Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
The phase 2 clinical trial of Otsuka/Visterra's anti-APRIL monoclonal antibody, sibeprenlimab, for the treatment of IgA nephropathy is published in the NEJM
8 November 2023
Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.
Drug Insights
4 min read
Exploring Metadoxine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
8 November 2023
This article summarized the latest R&D progress of Metadoxine, the Mechanism of Action for Metadoxine, and the drug target R&D trends for Metadoxine.
Latest Hotspot
3 min read
The first participant has been administered HG004 in an international phase 1/2 study against hereditary blindness, as disclosed by Huidagene Therapeutics
8 November 2023
HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.
Bio Sequence
2 min read
Biological Glossary | What is Intron?
8 November 2023
An intron, derived from the term "intragenic region", is a nucleotide sequence within a gene that does not directly code for proteins and does not remain in the final mature mRNA molecule following the gene's transcription.
Drug Insights
4 min read
Decoding Metyrosine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
8 November 2023
This article summarized the latest R&D progress of Metyrosine, the Mechanism of Action for Metyrosine, and the drug target R&D trends for Metyrosine.
Latest Hotspot
3 min read
The FDA gives the go-ahead to Novartis Cosentyx® - a first biological treatment innovation for hidradenitis suppurativa sufferers in roughly ten years
7 November 2023
Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.
Drug Insights
4 min read
Deep Scientific Insights on Mexazolam's R&D Progress, Mechanism of Action, and Drug Target
7 November 2023
This article summarized the latest R&D progress of Mexazolam, the mechanism of action for Mexazolam, and the drug target R&D trends for Mexazolam.
Latest Hotspot
3 min read
The FDA has greenlighted a replicable bioequivalent treatment for various inflammation-related disorders
7 November 2023
The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.
Bio Sequence
2 min read
Biological Glossary | What is Hairpin Sequence?
7 November 2023
In a hairpin sequence, the strand loops out and then come back to pair with itself, forming a double helix (the stem) ending in an unpaired loop.
Latest Hotspot
3 min read
The FDA has cleared Mersana Therapeutics to resume the Phase 1 clinical trial for XMT-2056, the company announced
7 November 2023
The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.
Drug Insights
4 min read
An In-depth Analysis of Midodrine Hydrochloride's R&D Progress and Mechanism of Action on Drug Target
7 November 2023
This article summarized the latest R&D progress of Midodrine Hydrochloride, the Mechanism of Action for Midodrine Hydrochloride, and the drug target R&D trends for Midodrine Hydrochloride.
Latest Hotspot
3 min read
Lirum Therapeutics reveals promising preliminary results of targeted clinical treatment LX-101's notable efficacy against children's sarcomas
7 November 2023
Lirum Therapeutics announces encouraging results on LX-101, an innovative, clinical-phase targeted treatment, showing significant preliminary efficacy against children's sarcomas.